Direct oral anticoagulation in AF – beware of underdosing particularly in the elderly, consider long-term adherence, understand anticoagulation strategies during ablation interventions and manage bleeds with reversal agents
What’s new in atrial fibrillation?
Printable Q&A for Offline SubmissionQuiz-summary
0 of 15 questions completed
Questions:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
Information
You have already completed the module before. Hence you can not start it again.
Module is loading…
You have to finish following quiz, to start this quiz:
Results
Results
Time has elapsed
Categories
- Not categorized 0%
-
Thank you, we will review your submission and notify you of your results via email.
If not received within 5 hours due to spam, don’t worry, it will show in your profile.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- Answered
- Review
- Question 1 of 15
1. Question
9. In the RE-DUAL PCI trial, dual antithrombotic therapy with dabigatran plus a P2Y12 inhibitor reduced the risk of bleeding compared to triple therapy with warfarin, AP2Y12 inhibitor and aspirin:
- Question 2 of 15
2. Question
10. In the RE-DUAL PCI trial intracranial haemorrhage occurred in what percentage of patients treated with dual therapy (dabigatran 150mg plus P2Y12 inhibitor)?
- Question 3 of 15
3. Question
1. Dabigatran therapy with a 150mg dose bid in AF patients was shown to be safe and effective with a hazard ratio of:
- Question 4 of 15
4. Question
2. In the RE-LY study, what percentage of patients was given a standard dose (150mg bid) as compared to a reduced dose (110mg bid)?
- Question 5 of 15
5. Question
3. In real-world patients, a dabigatran standard dose as compared to a low dose closely reflects what was seen in the RE-LY cohort:
- Question 6 of 15
6. Question
4. In real-world patients, use of FXa inhibitors such as rivaroxaban closely reflects what was seen in the relevant phase III trial:
- Question 7 of 15
7. Question
5. Real-world registries such as GLORIA-AF closely mimic actual phase III trials except that:
- Question 8 of 15
8. Question
6. In the real world internationally, what percentage of AF patients are still taking their medication after two years?
- Question 9 of 15
9. Question
7. When performing ablation in dabigatran-treated AF patients, anticoagulant therapy should be:
- Question 10 of 15
10. Question
8. The incidence of major bleeding events on dabigatran versus warfarin treatment during and up to eight weeks post-ablation was:
- Question 11 of 15
11. Question
11. The incidence of major bleeding on DOAC therapy that requires a reversal agent in the view of attending clinician is on average:
- Question 12 of 15
12. Question
12. Idarucizumab was registered in South Africa as the reversal agent for dabigatran in:
- Question 13 of 15
13. Question
13. Which of the following statements is false?
- Question 14 of 15
14. Question
14. Andexenet alfa, as a decoy factor X, has been approved in the USA and Europe as a reversal agent in patients treated with:
- Question 15 of 15
15. Question
15. Which statement is false?
Do you like this? Share with a colleague
